Adaptive Biotechnologies Current Financial Leverage
| ADPT Stock | USD 2.34 0.10 4.10% |
Adaptive Biotechnologies holds a debt-to-equity ratio of 0.214. At this time, Adaptive Biotechnologies' Net Debt is comparatively stable compared to the past year. Long Term Debt Total is likely to gain to about 44.2 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 130.6 M in 2024. Adaptive Biotechnologies' financial risk is the risk to Adaptive Biotechnologies stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Adaptive Biotechnologies' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Adaptive Biotechnologies' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Adaptive Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Adaptive Biotechnologies' stakeholders.
For most companies, including Adaptive Biotechnologies, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running Adaptive Biotechnologies Corp the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
Price Book 1.4161 | Book Value 2.126 | Operating Margin (1.00) | Profit Margin (1.32) | Return On Assets (0.17) |
Adaptive |
Adaptive Biotechnologies Financial Leverage Rating
Adaptive Biotechnologies Corp bond ratings play a critical role in determining how much Adaptive Biotechnologies have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Adaptive Biotechnologies' borrowing costs.| Piotroski F Score | 6 Healthy |
| Beneish M Score | -2.72 Unlikely Manipulator |
Adaptive Biotechnologies Debt to Cash Allocation
As Adaptive Biotechnologies Corp follows its natural business cycle, the capital allocation decisions will not magically go away. Adaptive Biotechnologies' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company currently holds 229.43 M in liabilities with Debt to Equity (D/E) ratio of 0.21, which may suggest the company is not taking enough advantage from borrowing. Adaptive Biotechnologies has a current ratio of 3.85, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Adaptive Biotechnologies until it has trouble settling it off, either with new capital or with free cash flow. So, Adaptive Biotechnologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Adaptive Biotechnologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Adaptive to invest in growth at high rates of return. When we think about Adaptive Biotechnologies' use of debt, we should always consider it together with cash and equity.Adaptive Biotechnologies Total Assets Over Time
Adaptive Biotechnologies Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Adaptive Biotechnologies' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Adaptive Biotechnologies, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a an Adaptive Biotechnologies debt ratio should be compared their industry average or other competing firms.Adaptive Net Debt
Net Debt |
|
Understaning Adaptive Biotechnologies Use of Financial Leverage
Adaptive Biotechnologies financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures Adaptive Biotechnologies's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Adaptive Biotechnologies assets, the company is considered highly leveraged. Understanding the composition and structure of overall Adaptive Biotechnologies debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it. Financial leverage can amplify the potential profits to Adaptive Biotechnologies' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Adaptive Biotechnologies' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Net Debt | 164.4 M | 172.6 M | |
| Long Term Debt | 302.4 K | 271.2 K | |
| Long Term Debt Total | 42.1 M | 44.2 M | |
| Short and Long Term Debt | 0.00 | 0.00 | |
| Short Term Debt | 9.4 M | 5 M | |
| Short and Long Term Debt Total | 229.4 M | 130.6 M | |
| Net Debt To EBITDA | (0.92) | (0.87) | |
| Debt To Equity | 0.45 | 0.48 | |
| Interest Debt Per Share | 1.07 | 0.64 | |
| Debt To Assets | 0.21 | 0.22 | |
| Long Term Debt To Capitalization | 0.30 | 0.31 | |
| Total Debt To Capitalization | 0.31 | 0.33 | |
| Debt Equity Ratio | 0.45 | 0.48 | |
| Debt Ratio | 0.21 | 0.22 | |
| Cash Flow To Debt Ratio | (1.12) | (1.06) |
Adaptive Biotechnologies Investors Sentiment
The influence of Adaptive Biotechnologies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Adaptive. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Adaptive Biotechnologies' public news can be used to forecast risks associated with an investment in Adaptive. The trend in average sentiment can be used to explain how an investor holding Adaptive can time the market purely based on public headlines and social activities around Adaptive Biotechnologies Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Adaptive Biotechnologies' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Adaptive Biotechnologies' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Adaptive Biotechnologies' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Adaptive Biotechnologies.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Adaptive Biotechnologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Adaptive Biotechnologies' short interest history, or implied volatility extrapolated from Adaptive Biotechnologies options trading.
Pair Trading with Adaptive Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptive Stock
| 0.78 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.75 | ME | 23Andme Holding | PairCorr |
Moving against Adaptive Stock
| 0.86 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
| 0.73 | DOMH | Dominari Holdings | PairCorr |
| 0.64 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.61 | VCEL | Vericel Corp Ord Downward Rally | PairCorr |
| 0.57 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Adaptive Biotechnologies Fundamentals Over Time. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Adaptive Stock analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 1.179 | Quarterly Revenue Growth (0.17) | Return On Assets (0.17) | Return On Equity (0.58) |
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.